Eli Lilly Expands Into Gene Editing With Verve Therapeutics Acquisition

Weight Loss drug maker Eli Lilly And Co (NYSE:LLY) has agreed to acquire Verve Therapeutics, Inc. (NASDAQ:VERV), a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease.

Verve’s lead program (VERVE-102) is a potential first-in-class in vivo gene editing medicine targeting PCSK9, a gene linked to cholesterol levels and cardiovascular health.

The treatment may be applicable for people who have heterozygous familial hypercholesterolemia (HeFH), a subset of ASCVD that affects 1 in 250 people in the general population, as well as certain patients with premature coronary artery disease (CAD).

Also Read: Eli Lilly Launches Flat Pricing For Zepbound, Capping Monthly Cost At $499

VERVE-102 is being evaluated in a Phase 1b clinical trial study and has ...